Oncobiologics, Liomont Partner To Introduce Biosimilars In Mexico
By Cyndi Root
Oncobiologics announced in a press release that it has partnered with Laboratorios Liomont to market biosimilar monoclonal antibody products to the Mexican market. Liomont will have the exclusive right to commercialize two of Oncobiologic’s biosimilars.
Alfredo Rimoch, CEO of Liomont, said, "This partnership is an important step toward introducing high-quality biotherapeutics to Mexico. Oncobiologics represents an ideal partner for Liomont's entry into the biologics market.”
Pankaj Mohan, of Oncobiologics, also said, "Liomont is a leader in small-molecule pharmaceuticals development, production and commercialization in Mexico, and we are excited to partner with them to bring important biologics to Mexico.” According to Mohan, the development of the company’s biosimilar products is progressing and the drugs should soon be in clinical trial programs.
Oncobiologics and Liomont Partnership
The partnership between Oncobiologics and Liomont is to develop, manufacture, and commercialize biosimilar products in Mexico. They did not release detailed financial terms, however Oncobiologics has agreed to conduct clinical trials and provide manufacturing for a commercial supply of the drugs in Mexico. Liomont is to pay licensing fees upfront, development milestone payments, and royalties.
About Oncobiologics
Oncobiologics is a biopharmaceutical company with R&D and manufacturing facilities in Cranbury, NJ. It focuses on biosimilars in the areas of immunology, immuno-oncology, and oncology. Currently in its pipeline are the following biosimilars and their indications:
- Humira – rheumatoid arthritis, Crohns, ulcerative arthritis, psoriasis
- Avastin – colorectal, lung
- Rituxin – non-Hodgkin’s lymphoma
- Herceptin – breast, colorectal cancer
- Erbitux – head and neck cancers
Oncobiologics calls its biosimilars development process the Biosymphony Model. In this model, the company brings together subject matter experts to leverage their knowledge and create products that meet regulatory requirements.
Over the past year, the company has been involved in several partnerships. Earlier in June, Oncobiologics announced a partnership with Ipca Laboratories from India for development and marketing of its antibody products in India. In August 2013, Oncobiologics and inVentiv Health partnered to develop all of the assets in Oncobiologic’s pipeline, with possible expansion to novel molecules.
About Laboratorios Liomont S.A. de C.V.
Laboratorios Liomont is a Mexican company established in 1938. It is one of the largest companies in Mexico and it is involved in drug development, manufacturing, and commercialization of prescription and over-the-counter (OTC) products. Prescription products include analgesics, antibiotics, and antivirals.